GB201402070D0 - Pharmaceutical compositions for the treatment of inflammatory disorders - Google Patents

Pharmaceutical compositions for the treatment of inflammatory disorders

Info

Publication number
GB201402070D0
GB201402070D0 GB201402070A GB201402070A GB201402070D0 GB 201402070 D0 GB201402070 D0 GB 201402070D0 GB 201402070 A GB201402070 A GB 201402070A GB 201402070 A GB201402070 A GB 201402070A GB 201402070 D0 GB201402070 D0 GB 201402070D0
Authority
GB
United Kingdom
Prior art keywords
treatment
pharmaceutical compositions
inflammatory disorders
disorders
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201402070A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Priority to GB201402070A priority Critical patent/GB201402070D0/en
Publication of GB201402070D0 publication Critical patent/GB201402070D0/en
Priority to ES15705777T priority patent/ES2788671T3/es
Priority to NZ72240315A priority patent/NZ722403A/en
Priority to US14/614,393 priority patent/US10493158B2/en
Priority to JP2016550646A priority patent/JP6633531B2/ja
Priority to EP15705777.9A priority patent/EP3102213B1/en
Priority to HRP20200605TT priority patent/HRP20200605T1/hr
Priority to CA2938217A priority patent/CA2938217C/en
Priority to AU2015215044A priority patent/AU2015215044B2/en
Priority to PCT/EP2015/052239 priority patent/WO2015117980A1/en
Priority to DK15705777.9T priority patent/DK3102213T3/da
Priority to UY0001035985A priority patent/UY35985A/es
Priority to TW104104150A priority patent/TWI697330B/zh
Priority to ARP150100350A priority patent/AR099306A1/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB201402070A 2014-02-07 2014-02-07 Pharmaceutical compositions for the treatment of inflammatory disorders Ceased GB201402070D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB201402070A GB201402070D0 (en) 2014-02-07 2014-02-07 Pharmaceutical compositions for the treatment of inflammatory disorders
DK15705777.9T DK3102213T3 (da) 2014-02-07 2015-02-04 Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
HRP20200605TT HRP20200605T1 (hr) 2014-02-07 2015-02-04 Farmaceutske kompozicije za liječenje inflamatornih poremećaja
AU2015215044A AU2015215044B2 (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders
US14/614,393 US10493158B2 (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders
JP2016550646A JP6633531B2 (ja) 2014-02-07 2015-02-04 炎症性障害の治療のための医薬組成物
EP15705777.9A EP3102213B1 (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders
ES15705777T ES2788671T3 (es) 2014-02-07 2015-02-04 Composiciones farmacéuticas para el tratamiento de afecciones inflamatorias
CA2938217A CA2938217C (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders
NZ72240315A NZ722403A (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders
PCT/EP2015/052239 WO2015117980A1 (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders
ARP150100350A AR099306A1 (es) 2014-02-07 2015-02-06 Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios
UY0001035985A UY35985A (es) 2014-02-07 2015-02-06 Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios.
TW104104150A TWI697330B (zh) 2014-02-07 2015-02-06 用於治療發炎疾病之醫藥組合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201402070A GB201402070D0 (en) 2014-02-07 2014-02-07 Pharmaceutical compositions for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
GB201402070D0 true GB201402070D0 (en) 2014-03-26

Family

ID=50390571

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201402070A Ceased GB201402070D0 (en) 2014-02-07 2014-02-07 Pharmaceutical compositions for the treatment of inflammatory disorders

Country Status (14)

Country Link
US (1) US10493158B2 (enExample)
EP (1) EP3102213B1 (enExample)
JP (1) JP6633531B2 (enExample)
AR (1) AR099306A1 (enExample)
AU (1) AU2015215044B2 (enExample)
CA (1) CA2938217C (enExample)
DK (1) DK3102213T3 (enExample)
ES (1) ES2788671T3 (enExample)
GB (1) GB201402070D0 (enExample)
HR (1) HRP20200605T1 (enExample)
NZ (1) NZ722403A (enExample)
TW (1) TWI697330B (enExample)
UY (1) UY35985A (enExample)
WO (1) WO2015117980A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
RU2724053C2 (ru) * 2015-11-30 2020-06-19 Анакор Фармасьютикалз, Инк. Фармацевтические составы для местного применения для лечения связанных с воспалением состояний
US20190100519A1 (en) * 2016-03-21 2019-04-04 Crystal Pharmatech Co., Ltd. Hydrochloride salt crystal of drug for treating or preventing jak-associated disease and preparation method thereof
CA3043396A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
PL3758708T3 (pl) 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
EP3823627A4 (en) 2018-07-17 2022-04-20 Insmed Incorporated CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60016384T2 (de) 1999-01-29 2005-12-01 Chugai Seiyaku K.K. Chondrogonese promotoren und indolin-2-on derivate
EP1391211A1 (en) 2001-04-27 2004-02-25 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
CA2577478A1 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5366233B2 (ja) * 2005-08-10 2013-12-11 塩野義製薬株式会社 口腔内崩壊錠剤
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
AR067562A1 (es) 2007-07-18 2009-10-14 Novartis Ag Compuestos heterociclicos inhibidores de kinasa
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2008291075A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2296475A4 (en) 2008-06-20 2014-03-05 Genentech Inc TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2863950B1 (en) 2012-06-22 2018-07-18 Galapagos NV Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
JP6041823B2 (ja) * 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
CA2938217A1 (en) 2015-08-13
ES2788671T3 (es) 2020-10-22
DK3102213T3 (da) 2020-05-04
UY35985A (es) 2015-09-30
WO2015117980A1 (en) 2015-08-13
TW201613601A (en) 2016-04-16
CA2938217C (en) 2023-03-07
AU2015215044B2 (en) 2020-04-09
EP3102213B1 (en) 2020-04-01
AU2015215044A1 (en) 2016-08-11
HRP20200605T1 (hr) 2020-07-10
AR099306A1 (es) 2016-07-13
EP3102213A1 (en) 2016-12-14
TWI697330B (zh) 2020-07-01
NZ722403A (en) 2019-09-27
JP6633531B2 (ja) 2020-01-22
US20150224199A1 (en) 2015-08-13
US10493158B2 (en) 2019-12-03
JP2017505330A (ja) 2017-02-16

Similar Documents

Publication Publication Date Title
IL246833A0 (en) New salts and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
IL256624B (en) Pharmaceutical compounds and preparations thereof for the treatment of inflammatory disorders
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL262348A (en) Preparations for the treatment of excessive radiation disorders
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3303556C0 (en) COMPOSITIONS FOR THE TREATMENT OF OSTEOCHONDRAL DISEASES
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders
GB201506419D0 (en) Methods for the treatment of inflammatory disorders
GB201506229D0 (en) Methods For the Treatment Of Inflammatory Disorders

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: ABBVIE DEUTSCHLAND GMBH & CO.KG

Free format text: FORMER OWNER: GALAPAGOS NV

Owner name: ABBVIE INC.

Free format text: FORMER OWNER: GALAPAGOS NV

Owner name: GALAPAGOS NV

Free format text: FORMER OWNER: GALAPAGOS NV

AT Applications terminated before publication under section 16(1)